RxDoctor Payments Data

William Price, MD

Psychiatry · East Liverpool, OHNPI 1710953674

Payments from drug & device makers

$1,679in general payments, 2019–2025

Across 95 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$434
  • Acadia Pharmaceuticals Inc$344
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$146
  • Teva Pharmaceuticals USA, Inc.$138
  • Johnson & Johnson$132
  • Otsuka America Pharmaceutical, Inc.$97
  • plus $389 from 12 others

What the payments were for

  • Food & beverage$1,64598%
  • Education$342%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,679 in reported general payments places this provider in the 75th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$99,546
Medicare patients
644
Services billed
1,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate51$144,277
NuedextaDextromethorphan Hbr/Quinidine97$111,480
Paliperidone ErPaliperidone225$95,897
Rivastigmine510$94,546
VraylarCariprazine Hcl74$94,359
NuplazidPimavanserin Tartrate20$60,399
TrintellixVortioxetine Hydrobromide161$56,748
RivastigmineRivastigmine Tartrate721$53,081
ExelonRivastigmine66$48,900
FanaptIloperidone36$48,875
RexultiBrexpiprazole40$38,692
Memantine Hcl742$32,855
AuvelityDextromethorphan Hbr/Bupropion40$28,008
Memantine Hcl ErMemantine Hcl248$27,780
NamzaricMemantine Hcl/Donepezil Hcl77$22,602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$132$144,27751 claims
AbbVieVraylar, Namzaric$434$116,961151 claims
Avanir Pharmaceuticals, Inc.Nuedexta$17$111,48097 claims
Acadia Pharmaceuticals IncNuplazid$344$60,39920 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$11$56,748161 claims
Vanda Pharmaceuticals Inc.Fanapt$23$48,87536 claims
Otsuka America Pharmaceutical, Inc.Rexulti$97$38,69240 claims
Axsome Therapeutics, Inc.Auvelity$30$28,00840 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in East Liverpool

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →